Breaking Finance News

PAREXEL International Corporation (NASDAQ:PRXL) has been downgraded to Market Perform in a statement by Wells Fargo & Co. earlier today.

Having a price of $57.88, PAREXEL International Corporation (NASDAQ:PRXL) traded 0.64% higher on the day. With the last stock price down -8.74% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. PRXL has recorded a 50-day average of $61.58 and a two hundred day average of $64.13. Trade Volume was down over the average, with 374,710 shares of PRXL changing hands under the typical 710,447

Wells Fargo & Co. has downgraded PAREXEL International Corporation (NASDAQ:PRXL) to Market Perform in a statement released on 11/23/2016.

On 11/17/2016, First Analysis released a statement about PAREXEL International Corporation (NASDAQ:PRXL) upped the target price from $0.00 to $62.00 that suggested an upside of 0.11%.

Recent Performance Chart

PAREXEL International Corporation (NASDAQ:PRXL)

PAREXEL International Corporation has PE ratio of 18.75 with a one year low of $51.16 and a one year high of $71.13 and has a market capitalization of $0.

A total of 11 brokerages have issued a ratings update on PAREXEL International Corporation. Five brokerages rating the company a strong buy, four brokerages rating the company a buy, six brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally one brokerage rating the company a sell with a 12-month price target of $68.68.

General Company Details For PAREXEL International Corporation (NASDAQ:PRXL)

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company's PI segment provides information technology solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.